Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Vascular Endothelial Growth Factor (VEGF) Concentration in Sera and Tumor Effusions from Patients with Ovarian Carcinoma

A. HARLOZIŇSKA, P. SEDLACZEK, J. KULPA, M. GRYBOS, E. WOJCIK, A. VAN DALEN and R. EINARSSON
Anticancer Research March 2004, 24 (2C) 1149-1158;
A. HARLOZIŇSKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. SEDLACZEK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. KULPA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. GRYBOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. WOJCIK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. VAN DALEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. EINARSSON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 24 no. 2C 1149-1158
PubMed 
15154640

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received November 5, 2003
  • Accepted February 25, 2004
  • Published online March 1, 2004.

Copyright & Usage 
Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. A. HARLOZIŇSKA1,
  2. P. SEDLACZEK1,
  3. J. KULPA3,
  4. M. GRYBOS2,
  5. E. WOJCIK3,
  6. A. VAN DALEN4 and
  7. R. EINARSSON5
  1. 1Department of Clinical Immunology, Wroclaw Medical University, Wroclaw
  2. 21st Department of Gynecology, Wroclaw Medical University, Wroclaw
  3. 3Department of Clinical Biochemistry, Oncology Center, M. Sklodowska-Curie Memorial Institute, Cracow, Poland
  4. 4Institute of Tumour Marker Oncology, Gouda, The Netherlands
  5. 5DiaSorin AB, Stockholm, Sweden
  1. Correspondence to: Antonina Harlozinska, MD, PhD, Chair and Department of Clinical Immunology, Wroclaw Medical University, Mikulicza-Radeckiego 7, PL-50-368 Wroclaw, Poland. Tel: +48 71 784-00-99, Fax: +48 784-01-00, e-mail: immuno{at}immuno.am.wroc.pl

Cited By...

  • 36 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 24 (2C)
Anticancer Research
Vol. 24, Issue 2C
March-April 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vascular Endothelial Growth Factor (VEGF) Concentration in Sera and Tumor Effusions from Patients with Ovarian Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Vascular Endothelial Growth Factor (VEGF) Concentration in Sera and Tumor Effusions from Patients with Ovarian Carcinoma
A. HARLOZIŇSKA, P. SEDLACZEK, J. KULPA, M. GRYBOS, E. WOJCIK, A. VAN DALEN, R. EINARSSON
Anticancer Research Mar 2004, 24 (2C) 1149-1158;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Vascular Endothelial Growth Factor (VEGF) Concentration in Sera and Tumor Effusions from Patients with Ovarian Carcinoma
A. HARLOZIŇSKA, P. SEDLACZEK, J. KULPA, M. GRYBOS, E. WOJCIK, A. VAN DALEN, R. EINARSSON
Anticancer Research Mar 2004, 24 (2C) 1149-1158;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?
  • Google Scholar

More in this TOC Section

  • Primary Synovial Sarcoma of the Bone: A Case Report and Literature Review
  • Melanoma of the Lower Limbs and Hips: A Surveillance, Epidemiology, and End Results Analysis of Epidemiology and Survival 2000-2019
  • Ganglioside GD2 Expression Is Associated With Unfavorable Prognosis in Early Triple-negative Breast Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire